MX2020002968A - Moduladores selectivos de p2x3. - Google Patents
Moduladores selectivos de p2x3.Info
- Publication number
- MX2020002968A MX2020002968A MX2020002968A MX2020002968A MX2020002968A MX 2020002968 A MX2020002968 A MX 2020002968A MX 2020002968 A MX2020002968 A MX 2020002968A MX 2020002968 A MX2020002968 A MX 2020002968A MX 2020002968 A MX2020002968 A MX 2020002968A
- Authority
- MX
- Mexico
- Prior art keywords
- selective
- antagonist
- modulators
- receptor antagonism
- warm
- Prior art date
Links
- 102100040460 P2X purinoceptor 3 Human genes 0.000 abstract 3
- 101710189970 P2X purinoceptor 3 Proteins 0.000 abstract 3
- 230000008485 antagonism Effects 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 208000010470 Ageusia Diseases 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 102100040479 P2X purinoceptor 2 Human genes 0.000 abstract 1
- 101710189968 P2X purinoceptor 2 Proteins 0.000 abstract 1
- 235000019666 ageusia Nutrition 0.000 abstract 1
- 208000013116 chronic cough Diseases 0.000 abstract 1
- 230000036327 taste response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Amplifiers (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Oscillators With Electromechanical Resonators (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762560077P | 2017-09-18 | 2017-09-18 | |
| US15/936,316 US10111883B1 (en) | 2017-09-18 | 2018-03-26 | Selective P2X3 modulators |
| PCT/IB2018/001513 WO2019064079A2 (en) | 2017-09-18 | 2018-09-14 | SELECTIVE MODULATORS OF P2X3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002968A true MX2020002968A (es) | 2020-08-17 |
Family
ID=63894683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002968A MX2020002968A (es) | 2017-09-18 | 2018-09-14 | Moduladores selectivos de p2x3. |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US10111883B1 (https=) |
| EP (2) | EP3684368B8 (https=) |
| JP (1) | JP7242681B2 (https=) |
| KR (1) | KR102713354B1 (https=) |
| CN (1) | CN111601601A (https=) |
| AU (1) | AU2018342751B2 (https=) |
| CA (1) | CA3076150C (https=) |
| ES (1) | ES2969868T3 (https=) |
| IL (2) | IL303257A (https=) |
| MX (1) | MX2020002968A (https=) |
| SG (1) | SG11202002460QA (https=) |
| WO (1) | WO2019064079A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113559104A (zh) * | 2018-10-05 | 2021-10-29 | 盐野义制药株式会社 | 慢性咳嗽治疗用药物 |
| CA3115939A1 (en) * | 2018-10-10 | 2020-04-16 | Bellus Health Cough Inc. | Treatment of pruritus with p2x3 antagonists |
| MX2021005424A (es) * | 2018-11-13 | 2021-06-15 | Bellus Health Cough Inc | Formas cristalinas de un compuesto de imidazopiridina sustituida y uso del mismo como modulador del receptor p2x3. |
| WO2020135771A1 (zh) * | 2018-12-29 | 2020-07-02 | 武汉朗来科技发展有限公司 | 杂环类化合物、中间体、其制备方法及应用 |
| AU2020228760A1 (en) * | 2019-02-25 | 2021-09-23 | Glaxosmithkline Intellectual Property (No. 3) Limited | Treatment with P2X3 modulators |
| CN112409331B (zh) * | 2019-08-21 | 2024-02-20 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| EP4103572A4 (en) | 2020-02-14 | 2024-03-06 | Bellus Health Cough Inc. | MAKING A P2X3 ANTAGONIST |
| JP2023513373A (ja) * | 2020-02-14 | 2023-03-30 | べルス・ヘルス・コフ・インコーポレーテッド | Ｐ２ｘ３修飾薬 |
| MX2022013499A (es) | 2020-04-27 | 2023-01-16 | Twist Bioscience Corp | Bibliotecas de ácidos nucleicos variantes para coronavirus. |
| WO2021244634A1 (zh) * | 2020-06-05 | 2021-12-09 | 武汉人福创新药物研发中心有限公司 | 咪唑并吡啶类化合物及其用途 |
| CN114085220B (zh) * | 2020-06-22 | 2023-06-16 | 上海海雁医药科技有限公司 | 取代的吗啉-4-羧酸酯衍生物、其组合物及医药上的用途 |
| AU2021302056B2 (en) * | 2020-06-29 | 2023-12-14 | Wuhan Ll Science And Technology Development Co., Ltd. | Crystalline form of heterocyclic compound, preparation method therefor and application thereof |
| US20230218661A1 (en) * | 2022-01-10 | 2023-07-13 | Sensory Cloud, Inc. | Isotonic or hypertonic salt-based compositions, treatments, devices, and articles for delivery of same to larynx |
| US20240408131A1 (en) * | 2020-07-06 | 2024-12-12 | Sensory Cloud, Inc. | Isotonic or hypertonic salt-based compositions |
| CN113912601B (zh) * | 2020-07-10 | 2023-06-06 | 上海拓界生物医药科技有限公司 | 一类新的咪唑并[1,2-a]吡啶类衍生物、其制备方法及医药用途 |
| EP4198034A4 (en) * | 2020-08-13 | 2024-01-17 | Tuojie Biotech (Shanghai) Co., Ltd. | BENZIMIDAZOLE DERIVATIVES, PRODUCTION PROCESS THEREOF AND MEDICAL USE THEREOF |
| CN116635389A (zh) * | 2021-01-29 | 2023-08-22 | 上海海雁医药科技有限公司 | 吗啉衍生物及其药物组合物和用途 |
| WO2022258059A1 (zh) * | 2021-06-10 | 2022-12-15 | 武汉朗来科技发展有限公司 | 一种药物组合物、制剂及其制备方法和应用 |
| CN115043836B (zh) * | 2021-08-20 | 2023-07-18 | 苏州璞正医药有限公司 | 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途 |
| CN120917022A (zh) | 2023-03-23 | 2025-11-07 | 葛兰素史密斯克莱知识产权(第3号)有限公司 | 氘代p2x3调节剂 |
| WO2026022326A1 (en) | 2024-07-25 | 2026-01-29 | Glaxosmithkline Intellectual Property (No.3) Limited | P2x3 antagonist formulation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012011518B8 (pt) * | 2009-11-18 | 2023-01-10 | Astrazeneca Ab | Compostos, composição farmacêutica, kit e usos de um composto |
| WO2011116392A2 (en) * | 2010-03-19 | 2011-09-22 | University Of Miami | Use of p2x purinergic receptor agonists to enhance insulin secretion in pancreatic beta cells |
| US9598409B2 (en) * | 2013-01-31 | 2017-03-21 | Neomed Institute | Imidazopyridine compounds and uses thereof |
| RU2650118C2 (ru) * | 2013-08-23 | 2018-04-09 | Афферент Фармасьютикалз Инк. | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться |
| HUE058009T2 (hu) * | 2014-12-09 | 2022-06-28 | Bayer Ag | 1,3-Tiazol-2-il szubsztituált benzamid-származékok |
| KR20180054843A (ko) * | 2015-09-29 | 2018-05-24 | 애퍼런트 파마슈티컬스 인크. | 기침 치료에 사용하기 위한 디아미노피리미딘 p2x3 및 p2x2/3 수용체 조정제 |
| US9907795B2 (en) * | 2016-01-08 | 2018-03-06 | Nerre Therapeutics Limited | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents |
| CN109996546B (zh) * | 2016-09-30 | 2023-06-27 | 阿沙纳生物科学公司 | P2x3和/或p2x2/3化合物及方法 |
-
2018
- 2018-03-26 US US15/936,316 patent/US10111883B1/en active Active
- 2018-09-14 JP JP2020537064A patent/JP7242681B2/ja active Active
- 2018-09-14 CN CN201880073147.XA patent/CN111601601A/zh active Pending
- 2018-09-14 AU AU2018342751A patent/AU2018342751B2/en active Active
- 2018-09-14 SG SG11202002460QA patent/SG11202002460QA/en unknown
- 2018-09-14 IL IL303257A patent/IL303257A/en unknown
- 2018-09-14 CA CA3076150A patent/CA3076150C/en active Active
- 2018-09-14 MX MX2020002968A patent/MX2020002968A/es unknown
- 2018-09-14 EP EP18860273.4A patent/EP3684368B8/en active Active
- 2018-09-14 EP EP23219770.7A patent/EP4331669A3/en active Pending
- 2018-09-14 ES ES18860273T patent/ES2969868T3/es active Active
- 2018-09-14 WO PCT/IB2018/001513 patent/WO2019064079A2/en not_active Ceased
- 2018-09-14 IL IL273348A patent/IL273348B2/en unknown
- 2018-09-14 US US16/647,821 patent/US20200230148A1/en not_active Abandoned
- 2018-09-14 KR KR1020207010982A patent/KR102713354B1/ko active Active
-
2020
- 2020-11-17 US US16/950,742 patent/US20210069201A1/en not_active Abandoned
-
2021
- 2021-06-29 US US17/362,063 patent/US20210322432A1/en not_active Abandoned
-
2022
- 2022-02-11 US US17/669,806 patent/US20220160724A1/en not_active Abandoned
- 2022-09-14 US US17/932,200 patent/US20230248736A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2969868T3 (es) | 2024-05-23 |
| CA3076150A1 (en) | 2019-04-04 |
| KR102713354B1 (ko) | 2024-10-02 |
| CA3076150C (en) | 2024-01-02 |
| EP3684368A2 (en) | 2020-07-29 |
| EP3684368B1 (en) | 2024-01-03 |
| EP3684368A4 (en) | 2021-05-26 |
| EP3684368B8 (en) | 2024-02-14 |
| US20230248736A1 (en) | 2023-08-10 |
| JP2020534355A (ja) | 2020-11-26 |
| IL273348B2 (en) | 2023-11-01 |
| IL273348A (en) | 2020-05-31 |
| SG11202002460QA (en) | 2020-04-29 |
| IL303257A (en) | 2023-07-01 |
| KR20200092938A (ko) | 2020-08-04 |
| US10111883B1 (en) | 2018-10-30 |
| EP4331669A3 (en) | 2024-05-01 |
| US20200230148A1 (en) | 2020-07-23 |
| IL273348B1 (en) | 2023-07-01 |
| US20210322432A1 (en) | 2021-10-21 |
| AU2018342751B2 (en) | 2023-06-15 |
| EP4331669A2 (en) | 2024-03-06 |
| US20210069201A1 (en) | 2021-03-11 |
| WO2019064079A3 (en) | 2019-05-16 |
| CN111601601A (zh) | 2020-08-28 |
| AU2018342751A1 (en) | 2020-04-23 |
| US20220160724A1 (en) | 2022-05-26 |
| WO2019064079A2 (en) | 2019-04-04 |
| JP7242681B2 (ja) | 2023-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020002968A (es) | Moduladores selectivos de p2x3. | |
| WO2016090329A3 (en) | Antibodies targeting g-protein coupled receptor and methods of use | |
| MX2016005560A (es) | Compuestos agonistas triples de glucagon-glp-1-gip. | |
| HK1254820A1 (zh) | 免疫检查点嵌合受体疗法 | |
| PH12020500255A1 (en) | Use of nk-1 receptor antagonist serlopitant in pruritus | |
| GB2563236B (en) | Improvements in or relating to well abandonment | |
| SA516370641B1 (ar) | مركبات حلقية غير متجانسة وطرق لاستخدامها | |
| MX2016005759A (es) | Derivados de piridina sustituidos, utiles como inhibidores de glucogeno sintasa cinasa 3 (gsk-3). | |
| TW201613884A (en) | Selective NR2B antagonists | |
| NO20211140A1 (en) | Improvements in or relating to well abandonment | |
| GB2568593B (en) | Improvements in or relating to well abandonment | |
| JOP20150177B1 (ar) | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 | |
| WO2017074798A3 (en) | Long-acting co-agonists of the glucagon and glp-1 receptors | |
| GB201713525D0 (en) | Improvements in or relating to well abandonment | |
| GB2574054B (en) | Improvements in or relating to well abandonment | |
| EA201890981A1 (ru) | Новые гетероциклические антиэстрогены | |
| GB2580738B (en) | Improvements in or relating to well abandonment | |
| IL242682B (en) | Ethynyl derivatives as metabotropic glutamate receptor antagonists | |
| MY195657A (en) | Liraglutide In Cardiovascular Conditions | |
| GB2567157B (en) | Improvements in or relating to well abandonment | |
| MX2018004256A (es) | Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos. | |
| GB201600977D0 (en) | Novel crystalline form of picoxystrobin, method of preparing use of the same | |
| GB201903803D0 (en) | Improvements in or relating to well abandonment | |
| PL3765475T3 (pl) | Podstawione rybonukleozydy pirydopirolopirymidynowe do zastosowań terapeutycznych | |
| GB2571207B (en) | Intelligent, real-time response to changes in oilfield equilibrium |